The availability of testing for myeloid genomic sequencing variants for driver MPN mutations (JAK2 V617F, CALR and MPL) when MPN is suspected is likely to increase the diagnosis of MPN’s in younger patients. This evidence concerns the gene MPL and myeloproliferative disorder.